PharmaNutra S.p.A.MIL: PHN

H1 2025 financial results

· Issued by PharmaNutra S.p.A.
H1_2025 FINANCIAL RESULTS

Sep 8th, 2025



HIGHLIGHTS H1 2025


4

HIGHLIGHTS
  • The results as of June 30, 2025, confirm, once again, a solid trend of organic growth in revenue with an increase of 10,4% compared to the same period of the previous year.

  • The contribution of new projects to revenues, although increased, remains marginal, while the associated development costs (around €4 million) have led to the anticipated limited reduction in operating margin.

  • The Net Financial Position as of June 30, 2025, is negative (-€5.1 million), compared to the positive balance of €5.6 million as of December 31, 2024 due to dividends distribution, Akern's earn out payment and working capital dynamics.





ECONOMIC AND FINANCIAL DATA


Attention: This is an excerpt of the original content. To continue reading it, access the original document here.

PharmaNutra S.p.A. on 6ix

Earlier from PharmaNutra

Later from PharmaNutra

All PharmaNutra news releases